Fragment‐Based Drug Discovery of Novel High‐affinity, Selective, and Anti‐inflammatory Inhibitors of the Keap1‐Nrf2 Protein‐Protein Interaction
Open Access
- 21 August 2025
- journal article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (39) , e202508121
Abstract
Activating the cytoprotective response of nuclear factor erythroid 2‐related factor 2 (Nrf2) can reduce oxidative stress and inflammation. A promising strategy is to inhibit the protein‐protein interaction between Kelch‐like ECH‐associated protein 1 (Keap1) and Nrf2 using noncovalent compounds that target the Keap1 Kelch domain. These compounds may be more specific than covalent Keap1‐reacting Nrf2 activators. However, the development of drug‐like noncovalent Keap1‐Nrf2 inhibitors faces challenges due to the size and polarity of the Kelch binding pocket. Here, we present a new series of noncovalent Keap1‐Nrf2 inhibitors developed from a weak fragment hit identified by crystallographic screening. A two‐step growing strategy and optimization guided by several X‐ray cocrystal structures led to compounds with low nanomolar affinities and complete selectivity for Keap1 in a panel of homologous Kelch domains. In cells, compounds 24 and 28 potently activated the expression of Nrf2‐controlled genes and showed anti‐inflammatory effects by downregulating NLRP3 inflammasome and STING signalling activation. RNA sequencing revealed activation of cytoprotective pathways and a different profile from typical covalent Nrf2 activators. This work highlights the potential of fragment‐based drug discovery for challenging targets like Keap1 and introduces novel Keap1‐Nrf2 inhibitors as chemical probes and drug leads.Keywords
Funding Information
- Lundbeck Foundation (R335‐2019‐2138)
- Lundbeck Foundation (R366‐2021‐270)
- China Scholarship Council (201908210314)
- China Scholarship Council (2017062200)
- Hartmann Fonden
- Hørslev-Fonden
- Fabrikant Einar Willumsens Mindelegat
- Eva og Henry Frænkels Mindefond
- National Institutes of Health (SC3GM141838)
- Horizon 2020
This publication has 43 references indexed in Scilit:
- Accelerating Drug Discovery With High‐Throughput Crystallographic Fragment Screening and Structural EnablementApplied Research, 2024
- Biomarkers of NRF2 signalling: Current status and future challengesRedox Biology, 2024
- Advances in developing noncovalent small molecules targeting Keap1Drug Discovery Today, 2023
- Fragment-based drug discovery supports drugging ‘undruggable’ protein–protein interactionsTrends in Biochemical Sciences, 2023
- Advances and challenges in therapeutic targeting of NRF2Trends in Pharmacological Sciences, 2023
- Improved synthesis of deoxyalpinoid B and quantification of antileishmanial activity of deoxyalpinoid B and sulforaphaneBioorganic & Medicinal Chemistry, 2022
- KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potentialMedicinal Research Reviews, 2022
- Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent CompoundsJournal of Medicinal Chemistry, 2021
- Lessons from Hot Spot Analysis for Fragment-Based Drug DiscoveryTrends in Pharmacological Sciences, 2015
- Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarizationAnalytical Biochemistry, 2004